Your browser is no longer supported. Please, upgrade your browser.
URGN UroGen Pharma Ltd. daily Stock Chart
URGN [NASD]
UroGen Pharma Ltd.
Index- P/E- EPS (ttm)-4.75 Insider Own0.70% Shs Outstand20.96M Perf Week4.53%
Market Cap614.76M Forward P/E- EPS next Y-5.45 Insider Trans11.30% Shs Float18.38M Perf Month-5.39%
Income-89.90M PEG- EPS next Q-1.70 Inst Own79.00% Short Float13.06% Perf Quarter-0.58%
Sales0.02M P/S34153.16 EPS this Y-124.10% Inst Trans-0.78% Short Ratio14.91 Perf Half Y-7.45%
Book/sh10.08 P/B2.91 EPS next Y-10.10% ROA-43.80% Target Price49.75 Perf Year-29.05%
Cash/sh7.54 P/C3.89 EPS next 5Y- ROE-47.00% 52W Range20.72 - 42.32 Perf YTD-12.11%
Dividend- P/FCF- EPS past 5Y- ROI-85.80% 52W High-33.03% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low36.78% ATR1.47
Employees100 Current Ratio11.30 Sales Q/Q- Oper. Margin- RSI (14)38.82 Volatility4.46% 4.71%
OptionableYes Debt/Eq0.00 EPS Q/Q16.60% Profit Margin- Rel Volume0.72 Prev Close29.33
ShortableYes LT Debt/Eq0.00 EarningsMar 05 BMO Payout- Avg Volume161.00K Price28.34
Recom1.90 SMA20-4.43% SMA50-10.22% SMA200-9.25% Volume88,066 Change-3.38%
Jan-09-20Initiated National Securities Neutral $37
May-30-19Initiated JP Morgan Neutral
May-29-19Initiated Goldman Neutral
Jan-29-19Initiated H.C. Wainwright Buy $82
Nov-08-18Resumed Jefferies Buy
Apr-04-18Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18Initiated Ladenburg Thalmann Buy $50
Nov-15-17Reiterated Oppenheimer Outperform $32 → $51
Nov-15-17Downgrade Raymond James Outperform → Mkt Perform
Feb-25-20 08:00AM  UroGen Pharma Announces March 2020 Investor Conference Schedule Business Wire
Feb-24-20 08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 2, 2020 Business Wire
Jan-30-20 08:59AM  Are Insiders Buying UroGen Pharma Ltd. (NASDAQ:URGN) Stock? Simply Wall St.
Jan-08-20 08:00AM  UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-19-19 08:00AM  UroGen Pharma Announces FDA Filing Acceptance and Priority Review of U.S. New Drug Application (NDA) for UGN-101 Business Wire
Dec-17-19 07:36PM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
Dec-16-19 12:00PM  Volatility 101: Should UroGen Pharma (NASDAQ:URGN) Shares Have Dropped 29%? Simply Wall St. +5.07%
Dec-06-19 08:00AM  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire +6.67%
Dec-01-19 03:06PM  Weekly CEO Buys Highlight GuruFocus.com
Nov-18-19 08:00AM  UroGen to Present at November 2019 Investor Conferences Business Wire
Nov-12-19 08:00AM  UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments Business Wire +13.58%
07:20AM  The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat Benzinga
Nov-11-19 08:00AM  UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers Business Wire
Nov-06-19 10:16AM  We're Not Very Worried About UroGen Pharma's (NASDAQ:URGN) Cash Burn Rate Simply Wall St.
08:00AM  UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019 Business Wire
Sep-30-19 08:00AM  UroGen To Present at October 2019 Investor Conference Business Wire
Sep-24-19 04:01PM  UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances Business Wire
10:25AM  UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer Business Wire
Sep-18-19 12:15PM  Does UroGen Pharma Ltd. (NASDAQ:URGN) Have A High Beta? Simply Wall St.
Sep-10-19 08:00AM  UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness Business Wire
Sep-06-19 04:05PM  UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Aug-13-19 03:05PM  Estimating The Intrinsic Value Of UroGen Pharma Ltd. (NASDAQ:URGN) Simply Wall St. +5.58%
Aug-12-19 04:23PM  UroGen Pharma Ltd. (URGN) Q2 2019 Earnings Call Transcript Motley Fool
Aug-10-19 07:11AM  3 Stocks the World's Best Investors Are Buying Right Now Motley Fool
Aug-09-19 08:00AM  UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments Business Wire
Aug-05-19 08:00AM  UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019 Business Wire
Jul-23-19 10:43AM  Here's Why the Best Is Yet to Come for UroGen Pharma Motley Fool
Jul-16-19 09:48AM  UroGen Pharma Sees Hammer Chart Pattern: Time to Buy? Zacks
Jul-05-19 05:14PM  Hedge Funds Have Never Been This Bullish On UroGen Pharma Ltd. (URGN) Insider Monkey
Jul-01-19 08:00AM  UroGen Pharma Joins Russell 3000® Index Business Wire
May-30-19 08:00AM  UroGen Pharma to Present at June 2019 Investor Conferences Business Wire
May-26-19 08:18AM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
May-20-19 12:48PM  These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month Motley Fool
May-09-19 01:23PM  UroGen Pharma Ltd. (URGN) Q1 2019 Earnings Call Transcript Motley Fool
08:00AM  UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments Business Wire
May-07-19 12:53PM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
May-06-19 11:00AM  What Are Analysts Saying About UroGen Pharma Ltd.'s (NASDAQ:URGN) Earnings Outlook? Simply Wall St.
May-05-19 04:25PM  UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial Business Wire
May-02-19 08:00AM  UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019 Business Wire
Apr-23-19 08:00AM  UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen Business Wire
Apr-20-19 07:02PM  3 International Companies Making Waves in the U.S. Soon Motley Fool
Apr-16-19 10:21AM  1 Under-the-Radar Healthcare Stock Wall Street Is Overlooking Motley Fool
Apr-05-19 09:12AM  UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer Business Wire
Mar-25-19 02:39PM  What Type Of Shareholder Owns UroGen Pharma Ltd.s (NASDAQ:URGN)? Simply Wall St.
Mar-05-19 08:00AM  UroGen Pharma to Present at March 2019 Investor Conferences Business Wire
Feb-28-19 11:37AM  UroGen Pharma Ltd. (URGN) Q4 2018 Earnings Conference Call Transcript Motley Fool
08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results Business Wire
Feb-21-19 08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019 Business Wire
Feb-19-19 08:15AM  Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes New Research Emphasizes Economic Growth GlobeNewswire
Feb-06-19 12:00PM  What Investors Should Know About UroGen Pharma Ltd.s (NASDAQ:URGN) Financial Strength Simply Wall St.
Jan-29-19 02:17PM  Don't Waste Your Money on Penny Stocks. These 3 Stocks Are Better Buys Motley Fool
Jan-28-19 04:05PM  UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares Business Wire -5.51%
Jan-24-19 12:26PM  Here's Why Urogen Pharma Fell as Much as 12.4% Today Motley Fool -7.47%
07:45AM  The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial Benzinga
Jan-23-19 10:16PM  UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares Business Wire -14.41%
07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  UroGen Pharma Announces Proposed Public Offering of Ordinary Shares Business Wire
Jan-08-19 08:00AM  UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire -5.87%
Jan-03-19 06:30AM  UroGen Pharma Appoints Elizabeth (Liz) Barrett as President and Chief Executive Officer Business Wire +6.87%
Dec-22-18 12:36AM  Is UroGen Pharma Ltd. (URGN) A Good Stock To Buy? Insider Monkey
Dec-20-18 10:07AM  How Many Insiders Sold UroGen Pharma Ltd. (NASDAQ:URGN) Shares? Simply Wall St.
Dec-17-18 08:00AM  UroGen Pharma Initiates Rolling Submission of New Drug Application (NDA) for UGN-101 for the Treatment of Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire
Dec-03-18 07:25AM  Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-12-18 08:00AM  UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment Business Wire
Nov-06-18 08:00AM  UroGen Pharma to Present at November 2018 Investor Conferences Business Wire
Nov-05-18 08:00AM  UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018 Business Wire
Oct-30-18 08:00AM  FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharmas UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Business Wire
Oct-24-18 08:50AM  Market Trends Toward New Normal in UROGEN PHARMA, Cimarex Energy, Boingo Wireless, TransCanada, EXTRACTION O&G, and ACADIA Pharmaceuticals Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire -5.82%
Oct-05-18 03:35PM  Shareholders Should Check The Ownership Structure Of UroGen Pharma Ltd (NASDAQ:URGN) Simply Wall St.
Sep-25-18 08:00AM  UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference Business Wire
Sep-11-18 08:00AM  Jones Woody Bryan Joins UroGen Pharma as Senior Vice President of Business Development Business Wire +6.24%
Aug-14-18 07:00AM  UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
06:30AM  UroGen Pharma Ltd. to Host Earnings Call ACCESSWIRE
Aug-08-18 08:00AM  UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer GlobeNewswire
Aug-07-18 08:00AM  UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 GlobeNewswire
Jul-11-18 08:00AM  UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) GlobeNewswire
Jul-10-18 08:00AM  UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors GlobeNewswire
Jun-13-18 08:00AM  UroGen Pharmas Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award GlobeNewswire
Jun-06-18 07:30AM  Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group Discovering Underlying Factors of Influence GlobeNewswire
Jun-05-18 08:00AM  UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance GlobeNewswire
May-29-18 08:00AM  UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-21-18 01:40PM  UroGen Pharma Announces Positive Interim Results from Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) GlobeNewswire
May-16-18 11:50AM  Urogen Pharma Ltd. (URGN) Q1 2018 Earnings Conference Call Transcript Motley Fool
May-15-18 08:00AM  UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments GlobeNewswire
06:43AM  Analysts Expect Breakeven For UroGen Pharma Ltd (NASDAQ:URGN) Simply Wall St.
May-08-18 08:00AM  UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018 GlobeNewswire
Apr-13-18 07:55AM  Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital New Research Emphasizes Economic Growth GlobeNewswire
Apr-04-18 08:00AM  Todays Research Reports on Stocks to Watch: UroGen Pharma and Novartis ACCESSWIRE +5.74%
Apr-03-18 08:32AM  UroGen Pharma Announces Presentation of Results from Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel) for Non-Surgical Treatment of Upper Tract Urothelial Cancer (UTUC) GlobeNewswire +23.68%
Mar-15-18 08:20AM  Research Report Identifies Prothena, UROGEN PHARMA, Mizuho Financial Group, 1-800 FLOWERS.COM, Willis Towers Watson Public, and First Connecticut with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  UroGen Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-08-18 08:00AM  UroGen Pharma to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 15, 2018 GlobeNewswire
Mar-07-18 08:00AM  UroGen to Present at March 2018 Investor Conferences GlobeNewswire
Feb-17-18 07:37PM  Urogen Pharma Ltd (URGN) and CoStar Group Inc (CSGP) Are Among Wildcat Capitals Top Winning Picks Insider Monkey
Feb-14-18 08:00AM  UroGen Pharma Strengthens Management Team with the Appointment of Stephen Mullennix as Chief Operating Officer GlobeNewswire
Jan-23-18 04:01PM  UroGen Pharma Announces Closing of Upsized Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option GlobeNewswire
Jan-18-18 07:10PM  UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares GlobeNewswire
Jan-16-18 04:05PM  UroGen Pharma Announces Proposed Public Offering of Ordinary Shares GlobeNewswire
Jan-08-18 08:00AM  UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer GlobeNewswire
Jan-02-18 08:00AM  UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PFREUNDSCHUH PETER P.Chief Financial OfficerFeb 20Sale29.6836010,6856,120Feb 24 04:53 PM
Mullennix StephenChief Operating OfficerFeb 14Sale28.0461217,1609,812Feb 18 02:33 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJan 27Sale29.2866719,5304,438Jan 28 05:15 PM
Mullennix StephenChief Operating OfficerJan 27Sale29.2668420,0148,665Jan 28 05:14 PM
Schoenberg MarkChief Medical OfficerJan 27Sale29.153229,3869,177Jan 28 05:10 PM
Barrett Elizabeth A.Chief Executive OfficerJan 03Option Exercise0.00105,6880122,236Jan 07 06:30 PM
Barrett Elizabeth A.Chief Executive OfficerNov 21Buy28.007,530210,84016,548Nov 22 03:34 PM
Barrett Elizabeth A.Chief Executive OfficerNov 20Buy28.007,470209,1609,018Nov 22 01:35 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerNov 20Sale28.4135410,0573,439Nov 22 01:29 PM
Schoenberg MarkChief Medical OfficerNov 19Buy28.171,96055,2137,967Nov 21 08:49 PM
Barrett Elizabeth A.Chief Executive OfficerNov 15Buy26.001,54840,2481,548Nov 18 07:32 PM
Mullennix StephenChief Operating OfficerNov 14Sale26.0060815,8067,683Nov 18 04:04 PM